Postbiotics are the bioactive compounds (metabolites, short-chain fatty acids, cell wall fragments, and functional proteins) that probiotic organisms produce during fermentation, and a growing body of clinical work plus the ISAPP 2021 consensus definition now puts them forward as the next stage of gut health beyond live-bacteria probiotics. They are shelf-stable, work without surviving the GI tract intact, and deliver consistent activity across very different microbiomes. For supplement brands, that means simpler formulation, cleaner labels, and a real chance to occupy a category position that probiotics no longer offer.
If you have been in the supplement industry for any length of time, you have watched gut health evolve from a niche category into one of the most competitive spaces in natural products. Probiotics led that charge, and they have been enormously successful. But a growing body of science and a new generation of ingredient companies are making a bold claim: probiotics have peaked, and postbiotics are what comes next.
That is not just speculation from startups chasing buzz. It is the position of companies like Nordic Rebalance, founded in 2006, which is now expanding its oat-based, metabolite-rich postbiotic platform across European markets (NutraIngredients, March 2026). It is backed by clinical research from ADM, one of the world's largest nutrition ingredient suppliers. And it is reshaping how formulators, brand founders, and contract manufacturers think about gut health product development.
Here is what postbiotics are, why they matter, and what it means for your next product.
What are postbiotics, and how do they differ from probiotics and prebiotics?
To understand postbiotics, it helps to see the full evolutionary arc of gut health science:
- Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. They are the "good bacteria" consumers know well, including Lactobacillus, Bifidobacterium, and their many strains.
- Prebiotics are non-digestible fibers and compounds that feed those beneficial bacteria. Think inulin, FOS, and resistant starches.
- Postbiotics are the bioactive compounds produced by probiotic organisms during fermentation. That includes metabolites, short-chain fatty acids (SCFAs), cell wall fragments, and functional proteins. For more on related ingredients, see our supplement ingredient library.
The International Scientific Association for Probiotics and Prebiotics (ISAPP) formally defined postbiotics in 2021 as a "preparation of inanimate microorganisms and/or their components that confers a health benefit on the host" (Salminen et al., Nature Reviews Gastroenterology & Hepatology, 2021). That definition was a turning point. It gave the category scientific legitimacy and a clear regulatory framework.
The key distinction? Postbiotics do not need to be alive to work. That single fact changes everything about stability, shelf life, formulation flexibility, and supply chain management.
Why do experts say the probiotic category has peaked?
Nordic Rebalance, the Danish biotech founded in 2006, has been making a provocative case as it expands its B2B postbiotic business beyond Denmark and Sweden into broader European markets: the probiotic category, while massive, has hit a ceiling.
Their argument rests on several structural challenges that probiotic products face:
Viability and stability. Live organisms are inherently fragile. They require cold chain logistics, careful formulation to survive stomach acid, and have limited shelf lives. Every step from manufacturing to the consumer's medicine cabinet introduces risk of degradation.
Strain specificity and consumer confusion. The probiotic market is crowded with strain-specific claims that most consumers do not understand. The difference between Lactobacillus rhamnosus GG and Lactobacillus acidophilus LA-5 is meaningful to scientists, but to the average shopper, it is noise.
Individual variability. Emerging research on "digital gut twins" (computational models of individual microbiome responses) has shown that probiotic efficacy varies dramatically from person to person. What works for one consumer's microbiome may have minimal effect on another's (Zmora et al., Cell, 2018).
Postbiotics sidestep many of these problems. They are shelf-stable at room temperature, do not require strain-specific survival through the GI tract, and deliver consistent bioactive compounds regardless of the host's existing microbiome composition.
What does the research show about postbiotic efficacy?
ADM's metabolic health findings
One of the more compelling clinical data points comes from ADM (Archer Daniels Midland), which has studied the postbiotic Bifidobacterium animalis subsp. lactis CECT 8145. Their research demonstrated improvements in metabolic health markers (Pedret et al., International Journal of Obesity, 2019). It is a significant finding because it extends the postbiotic value proposition beyond digestive comfort into metabolic wellness, a much larger addressable market.
This is particularly relevant for brands targeting consumers who are interested in weight management, blood sugar support, or metabolic syndrome. Those categories overlap heavily with the growing GLP-1 drug transition market.
The gut barrier connection
Postbiotics appear to be especially promising for gut barrier integrity. Nordic Rebalance's oat-based postbiotic platform is specifically focused on gut barrier function, supporting the intestinal lining that prevents unwanted substances from entering the bloodstream.
This is significant because increased intestinal permeability (sometimes called "leaky gut" in consumer-facing language) has been linked in research to a range of health concerns, from autoimmune conditions to systemic inflammation (Camilleri, Gut, 2019). A postbiotic that supports gut barrier function addresses a root cause rather than a symptom.
HMO science enters the adult market
Perhaps the most fascinating frontier in postbiotic science involves human milk oligosaccharides (HMOs). Research initiatives from North Carolina State University with nearly two decades of foundational work are expanding HMO science beyond infant nutrition into the adult gut health space.
HMOs are complex sugars naturally found in breast milk that serve as prebiotics for beneficial gut bacteria, and when metabolized, they produce postbiotic compounds (Bode, Glycobiology, 2012). The translation of this science to adult applications represents a potentially transformative new ingredient category for supplement brands.
What does this mean for supplement brand founders?
If you are developing or reformulating gut health products, the postbiotic trend has several practical implications.
1. Formulation advantages
Postbiotics offer significant formulation flexibility that probiotics simply cannot match:
- Room-temperature stability eliminates cold chain requirements and reduces logistics costs
- Longer shelf life means less waste and more forgiving inventory management
- Format versatility. Postbiotics work in capsules, powders, gummies, beverages, and even functional foods without the viability concerns of live organisms (see our manufacturing capabilities for available formats)
- Combination-friendly. Easier to formulate with other active ingredients without worrying about interactions that might kill live bacteria
2. Cleaner label storytelling
Consumers are increasingly sophisticated about gut health. The postbiotic narrative ("the beneficial compounds your body actually uses, delivered directly") is clean, intuitive, and differentiated. It answers the question consumers are already asking: If probiotics work because of what they produce, why not just take what they produce?
3. Regulatory positioning
Because postbiotics are not live organisms, they face different (and in many cases simpler) regulatory pathways in certain jurisdictions. For Canadian brands navigating the NPN (Natural Product Number) application process, or US brands dealing with GRAS (Generally Recognized as Safe) determinations, postbiotics may offer a more straightforward path to market depending on the specific ingredient.
4. Differentiation in a crowded market
The probiotic shelf is saturated. Consumers face dozens of competing products with CFU counts and strain names as the primary differentiators. Postbiotics offer a genuine "next generation" positioning that stands apart, not as a replacement for probiotics, but as an evolution of the category.
How fast is the postbiotic competitive landscape moving?
The gut health market is described by industry analysts as entering its next phase, shaped by sharper science, smarter consumers, and big opportunities. Postbiotics are a central part of that shift.
Consider the signals:
- Nordic Rebalance is actively expanding its B2B postbiotic supply chain across Europe, specifically targeting supplement and functional food manufacturers
- ADM, a global ingredient giant, is investing in clinical research on postbiotic strains, a clear indicator of where the major players expect the market to move
- HMO science is transitioning from infant-only applications to adult gut health, opening entirely new ingredient categories
- The broader gut health trend continues to converge with other high-growth categories: metabolic health, mental wellness (the gut-brain axis), skin health (the gut-skin axis), and healthy aging
For brand founders and formulators, the window to establish a postbiotic product position is open now, but it will not stay uncrowded for long.
How should you evaluate postbiotic ingredients for your formulation?
If you are considering a postbiotic formulation, here are the key questions to ask your ingredient suppliers:
-
What specific metabolites or bioactive compounds does this postbiotic contain? Look for characterized compounds such as SCFAs (butyrate, propionate, acetate), bacteriocins, or specific cell wall components, not vague "fermentation byproduct" descriptions.
-
Is there clinical evidence for the specific postbiotic preparation? Not all postbiotics are created equal. Ask for human clinical data, not just preclinical or in vitro studies.
-
What is the standardization method? How is potency measured and guaranteed? CFU counts do not apply to postbiotics, so the standardization metric matters.
-
What is the intellectual property landscape? Some postbiotic preparations are patented. Understand what you are licensing and what exclusivity looks like.
-
What claims can you support? Work with your regulatory team to ensure the clinical evidence supports the specific health claims you want to make on your label.
FAQ
Are postbiotics safer than probiotics?
For most healthy adults, both have strong safety records. Postbiotics offer one practical safety advantage: because they are non-viable, they cannot colonize unexpectedly or cause issues in immunocompromised users, a documented (if rare) concern with live probiotic strains (Doron and Snydman, Clinical Infectious Diseases, 2015). For consumer-facing claims, brands should stick to structure-function language.
Can postbiotics be combined with probiotics in the same product?
Yes. Many "next generation" gut health products include both, with the probiotic delivering live activity in the GI tract and the postbiotic providing immediately available bioactive compounds. The combination formats well in capsules, powders, and stick packs. See our private label and white label supplement options for formats that support combination products.
Do postbiotics need to be refrigerated?
In most cases, no. Room-temperature stability is one of the category's biggest formulation advantages, though shelf life and storage requirements vary by specific ingredient. Always confirm with the supplier's stability data.
How do postbiotic claims work under Health Canada's NPN process?
Postbiotic ingredients are evaluated on the same basis as other natural health products: the specific ingredient, the dose, and the supporting evidence. Some characterized postbiotic compounds have established Health Canada monographs, while novel preparations may require Product License submissions with full evidence packages. Our NPN application service walks through the documentation required for new ingredients.
What is the difference between postbiotics and fermented food extracts?
Postbiotics, as defined by ISAPP, are preparations of inanimate microorganisms and/or their components with documented health benefits. Generic fermented food extracts may contain similar compounds but are not necessarily characterized, standardized, or clinically studied. The distinction matters for label claims and for differentiation.
Are postbiotics suitable for sensitive consumers?
In general, yes, because they avoid the live-organism considerations relevant to a small subset of users. As always, the specific formulation, dose, and target audience determine the appropriate disclaimers and contraindications.
The bottom line
Gut health is not going away. If anything, it is becoming more central to how consumers think about overall wellness. But the tools of gut health are evolving. Probiotics established the category and remain important. Prebiotics added the feeding strategy. Postbiotics complete the picture by delivering the beneficial end-products directly.
For supplement entrepreneurs, brand founders, and formulators, postbiotics represent one of the most compelling opportunities in the gut health space today: strong emerging science, clear consumer messaging, formulation advantages over live organisms, and a market position that is still early enough to own.
The brands that move thoughtfully now, investing in quality postbiotic ingredients with solid clinical backing, will be the ones defining this category as it matures. If you are exploring a postbiotic SKU and want to talk through formulation and timelines, start a project with us.
Sources: NutraIngredients coverage of Nordic Rebalance B2B expansion (March 2026); ADM postbiotic clinical research on Bifidobacterium animalis subsp. lactis CECT 8145 (Pedret et al., 2019); Ummino/Hummino HMO research from NC State University; ISAPP postbiotic consensus definition (Salminen et al., Nature Reviews Gastroenterology & Hepatology, 2021); Bode, "Human milk oligosaccharides," Glycobiology, 2012; Camilleri, "Leaky gut: mechanisms, measurement and clinical implications in humans," Gut, 2019; Zmora et al., "Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics," Cell, 2018; Doron and Snydman, "Risk and Safety of Probiotics," Clinical Infectious Diseases, 2015; NutraIngredients gut health market analysis (March 23-27, 2026).
